2 terminated, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
Follow fedratinib: new trials by email Literature Review of fedratinib trials Research Report on fedratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Completed | Celgene | 202 | 2019-09-09 | 2025-08-28 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 3 | Terminated | Celgene | 38 | 2019-03-27 | 2024-12-12 |
| Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis SAR302503, Placebo - Hematopoietic Neoplasm | Phase 3 | Terminated | Bristol-Myers Squibb | 289 | 2011-12-31 | 2026-08-11 |
Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Hematologic Neoplasms (1)
Celgene (2) · Bristol-Myers Squibb (1)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Hungary (2) · Ireland (2) · Italy (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2)
PMID 26181658, PMID 38838026, PMID 39265613
2018 (2)